ER contraceptive market battles over original & generics

By Nho, Byung Chul | translator Choi HeeYoung

22.07.06 14:36:30

가나다라 0

Attention to strategies such as Hyundai Pharmaceutical, Bayer, and GL Pharma

Trial for confirmation of scope of rights for pharmaceutical patents and lawsuit on the merits of patent infringement also issue

GL Pharma has become a supplier of 28% of the Levonorgestrel market share in 3 years

Norevo (Levonorostrel 0.75mg) and Elaone (Ulipristal Acetate 30mg), which Hyundai Pharmaceutical received import licenses from HRA Pharma in 2001 and 2011, by a 10-year gap, are emerging as icons of changes in the emergency contraceptive market. Emergency contraceptives have been submitted to the Central Pharmaceutical Review Committee of the MFDS and classified and maintained as Rx drugs during the reclassification process of Rx drugs vs OTC.

In 2014, seven years after Norevo, the first product of this series, was approved, the emergency contraceptive market showed box-office performance after forming about 8.7 billion won in appearance.

In the past five years, the CAGR has been showi

Nho, Byung Chul(sasiman@dailypharm.com)

If you want to see the full article, please JOIN US (click)